Healthcare company MediArk (CEO Lee Chan-hyung) has signed a business agreement with K-DOC (CEO Cho Seung-kook), an overseas medical expansion platform company, aiming to expand into the global healthcare market.
Through this agreement, the two companies plan to enter overseas healthcare markets in earnest, primarily targeting the Middle East region, by combining MediArk's multilingual AI healthcare platform 'Simtomi-Care,' developed by MediArk, with K-DOC's global healthcare network and specialized personnel.
Simtomi-Care is a service where patients conduct multilingual medical questionnaires using mobile devices prior to visiting medical institutions, and this information is converted into professional medical terminology to assist medical staff in writing electronic medical records.
Through such a system, hospitals can improve efficiency in the treatment process and significantly reduce consultation time. It also minimizes cases where patients might overlook important symptoms.
K-DOC is a platform specialized in global medical expansion, providing consulting for overseas hospital operation and establishment, based on Korean medical professionals.
Recently, it has successfully carried out various global medical projects, including those in the United States and the Middle East region, expanding its international presence.
The two companies plan to further reinforce the significance of this agreement by jointly participating in the medical volunteer activities of the World Taekwondo Federation, which will be held in a refugee camp in Jordan next April.
Cho Seung-kook, CEO of K-DOC, stated, "Korean medical technology and IT services play an important role in the global healthcare market," adding, "We have high expectations that this collaboration will further promote Korea's healthcare IT capabilities globally."
Lee Chan-hyung, CEO of MediArk, said, "Through this agreement, we will make efforts to ensure that innovative AI healthcare technology practically contributes to overseas medical fields," adding, "We will continue to strive to enable Korea’s excellent medical infrastructure to more easily expand overseas."
Meanwhile, MediArk was recognized this year by the Ministry of SMEs and Startups as a venture enterprise in the category of innovative growth and continues to carry out research on innovative medical technology development at its laboratory within Seoul Biohub.
Healthcare company MediArk (CEO Lee Chan-hyung) has signed a business agreement with K-DOC (CEO Cho Seung-kook), an overseas medical expansion platform company, aiming to expand into the global healthcare market.
Through this agreement, the two companies plan to enter overseas healthcare markets in earnest, primarily targeting the Middle East region, by combining MediArk's multilingual AI healthcare platform 'Simtomi-Care,' developed by MediArk, with K-DOC's global healthcare network and specialized personnel.
Simtomi-Care is a service where patients conduct multilingual medical questionnaires using mobile devices prior to visiting medical institutions, and this information is converted into professional medical terminology to assist medical staff in writing electronic medical records.
Through such a system, hospitals can improve efficiency in the treatment process and significantly reduce consultation time. It also minimizes cases where patients might overlook important symptoms.
K-DOC is a platform specialized in global medical expansion, providing consulting for overseas hospital operation and establishment, based on Korean medical professionals.
Recently, it has successfully carried out various global medical projects, including those in the United States and the Middle East region, expanding its international presence.
The two companies plan to further reinforce the significance of this agreement by jointly participating in the medical volunteer activities of the World Taekwondo Federation, which will be held in a refugee camp in Jordan next April.
Cho Seung-kook, CEO of K-DOC, stated, "Korean medical technology and IT services play an important role in the global healthcare market," adding, "We have high expectations that this collaboration will further promote Korea's healthcare IT capabilities globally."
Lee Chan-hyung, CEO of MediArk, said, "Through this agreement, we will make efforts to ensure that innovative AI healthcare technology practically contributes to overseas medical fields," adding, "We will continue to strive to enable Korea’s excellent medical infrastructure to more easily expand overseas."
Meanwhile, MediArk was recognized this year by the Ministry of SMEs and Startups as a venture enterprise in the category of innovative growth and continues to carry out research on innovative medical technology development at its laboratory within Seoul Biohub.